Compass Therapeutics says a treatment evaluating its cancer treatment didn’t meet the secondary endpoint for an unexpected ...
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US ...
On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...
Shares of several pharmaceutical companies were up after President Trump signed an executive order aimed at accelerating research, development access to psychedelic medicines for the treatment of ...
(NASDAQ:KYMR) is among the best biotech stocks. TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug ...
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday. The deal adds more than 120 treatments, including ...
After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...
A Woburn biotechnology company laid off more than 200 Massachusetts employees last week, and state filings warn more cuts may ...
State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...
Sunnier conditions in the forecast after ‘Biotech Winter?’ Participants in the BizWest’s Life Sciences CEO Roundtable hosted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results